CG
ALDX icon

Cutler Group’s Aldeyra Therapeutics ALDX Stock Holding History

Cutler Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-800
Closed -$2K – 5303
2021
Q3 		$2K Buy
+800
New +$7.34K ﹤0.01% 4954
2018
Q4 		– Sell
-8,200
Closed -$4K – 3863
2018
Q3 		$4K Buy
+8,200
New +$66.5K ﹤0.01% 3131

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Cutler Group's ALDX Position: Q3 2022 in Review

Cutler Group sold out of Aldeyra Therapeutics (ALDX) in Q3 2022, closing a stake of 1,596 shares — an estimated $6K sold.

Cutler Group first reported a position in ALDX in Q2 2018 and held it in 6 quarters. The position peaked at $102K in Q3 2021. 89 funds tracked by Wall St. Rank hold ALDX as of Q3 2022.

  • Cutler Group reported no remaining Aldeyra Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 1,596 Aldeyra Therapeutics shares in Q3 2022, an estimated $6K.
  • Cutler Group first reported a position in Aldeyra Therapeutics in Q2 2018 and held it in 6 quarters.
  • Cutler Group's Aldeyra Therapeutics position peaked at $102K in Q3 2021.
  • 89 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.